Amylyx Pharmaceuticals Stock Discussion

Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist Avexitide.
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has recently announced the acquisition of avexitide from Eiger BioPharmaceuticals, Inc. Avexitide has already garnered considerable attention for its potential therapeutic benefits and has received designations from the U.S. Food and Drug Administration (FDA). This article delve...